Prana Biotechnology EBITDA 2010-2021 | ATHE
Prana Biotechnology ebitda from 2010 to 2021. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Prana Biotechnology Annual EBITDA
(Millions of US $) |
| 2021 |
$-11 |
| 2020 |
$-9 |
| 2019 |
$-9 |
| 2018 |
$-6 |
| 2017 |
$-5 |
| 2016 |
$-6 |
| 2015 |
$-9 |
| 2014 |
$-17 |
| 2013 |
$-13 |
| 2012 |
$-8 |
| 2011 |
$-6 |
| 2010 |
$-4 |
| 2009 |
$-6 |
Prana Biotechnology Quarterly EBITDA
(Millions of US $) |
| 2021-06-30 |
|
| 2020-12-31 |
|
| 2020-06-30 |
|
| 2019-12-31 |
|
| 2019-06-30 |
|
| 2018-12-31 |
|
| 2018-06-30 |
|
| 2017-12-31 |
|
| 2017-06-30 |
|
| 2016-12-31 |
|
| 2016-06-30 |
|
| 2015-12-31 |
|
| 2015-06-30 |
|
| 2014-12-31 |
|
| 2014-06-30 |
|
| 2013-12-31 |
|
| 2013-06-30 |
|
| 2012-12-31 |
|
| 2012-06-30 |
|
| 2011-12-31 |
|
| 2011-06-30 |
|
| 2010-12-31 |
|
| 2010-06-30 |
|
| 2009-12-31 |
|
| 2009-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.015B |
$0.003B |
|
Prana Biotechnology was established to commercialize research into Alzheimer's disease and other major age-related degenerative disorders. Their mission is to develop diagnostic and therapeutic drugs to treat the central disease pathways that cause degeneration of the brain as the aging process progresses. Prana's technology has emerged from its researchers at prominent international institutions such as Massachusetts General Hospital at Harvard Medical School and the University of Melbourne.
|
